CD19 tumors were effectively suppressed in the HIP CAR T group, while the tumor burden in the allo CAR T group was similar to the group not receiving any CAR T product (Fig. 8l; Supplementary Fig. 14g). The gene discussed is CD19; the disease is neoplasm.